Nadia Amboldi

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.

Giampaolo Merlini, E Ascari, Nadia Amboldi et al. · Proceedings of the National Academy of Sciences · 1995 · 204 citations

Life Sciences, Biochemistry, Pharmacology +14

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Elena Ardini, Roberta Bosotti, Andrea Borgia et al. · Molecular Oncology · 2014 · 153 citations · Full text

Medicine, Cancer Biology, Oncology +17

Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor

Maria Gabriella Brasca, Nadia Amboldi, Dario Ballinari et al. · Journal of Medicinal Chemistry · 2009 · 128 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury

Paola Magnaghi, Barbara Salom, Liviana Cozzi et al. · Molecular Cancer Therapeutics · 2017 · 91 citations · Full text

Medicine, Oncology, Pharmacology +16